Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.
Real-world data on the effectiveness of glecaprevir/pibrentasvir (GLE/PIB) for patients with HCV infection and compensated cirrhosis is limited, especially for the 8-week regimen and in an Asian population. This retrospective study enrolled 159 consecutive patients with HCV and compensated cirrhosis...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0272567 |
| _version_ | 1798032669855973376 |
|---|---|
| author | Yung-Hsin Lu Chung-Kuang Lu Chun-Hsien Chen Yung-Yu Hsieh Shui-Yi Tung Yi-Hsing Chen Chih-Wei Yen Wei-Lin Tung Kao-Chi Chang Wei-Ming Chen Sheng-Nan Lu Chao-Hung Hung Te-Sheng Chang |
| author_facet | Yung-Hsin Lu Chung-Kuang Lu Chun-Hsien Chen Yung-Yu Hsieh Shui-Yi Tung Yi-Hsing Chen Chih-Wei Yen Wei-Lin Tung Kao-Chi Chang Wei-Ming Chen Sheng-Nan Lu Chao-Hung Hung Te-Sheng Chang |
| author_sort | Yung-Hsin Lu |
| collection | DOAJ |
| description | Real-world data on the effectiveness of glecaprevir/pibrentasvir (GLE/PIB) for patients with HCV infection and compensated cirrhosis is limited, especially for the 8-week regimen and in an Asian population. This retrospective study enrolled 159 consecutive patients with HCV and compensated cirrhosis who were treated with GLE/PIB at a single center in Taiwan. Sustained virological response (SVR) and adverse events (AEs) were evaluated. Among the 159 patients, 91 and 68 were treated with GLE/PIB for 8 and 12 weeks, respectively. In the per protocol analysis, both the 8- and 12-week groups achieved 100% SVR (87/87 vs. 64/64); and in the evaluable population analysis, 95.6% (87/91) of the 8-week group and 94.1% (64/68) of the 12-week group achieved SVR. The most commonly reported AEs, which included pruritus (15.4% vs. 26.5%), abdominal discomfort (9.9% vs. 5.9%), and skin rash (5.5% vs. 5.9%), were mild for the 8- and 12-week groups. Two patients in the 8-week group exhibited total bilirubin elevation over three times the upper normal limit. One of these two patients discontinued GLE/PIB treatment after 2 weeks but still achieved SVR. Both 8- and 12-week GLE/PIB treatments are safe and effective for patients of Taiwanese ethnicity with HCV and compensated cirrhosis. |
| first_indexed | 2024-04-11T20:17:36Z |
| format | Article |
| id | doaj.art-fc0f2f09b71f471dacc0d8df40376f44 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-11T20:17:36Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-fc0f2f09b71f471dacc0d8df40376f442022-12-22T04:04:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01178e027256710.1371/journal.pone.0272567Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.Yung-Hsin LuChung-Kuang LuChun-Hsien ChenYung-Yu HsiehShui-Yi TungYi-Hsing ChenChih-Wei YenWei-Lin TungKao-Chi ChangWei-Ming ChenSheng-Nan LuChao-Hung HungTe-Sheng ChangReal-world data on the effectiveness of glecaprevir/pibrentasvir (GLE/PIB) for patients with HCV infection and compensated cirrhosis is limited, especially for the 8-week regimen and in an Asian population. This retrospective study enrolled 159 consecutive patients with HCV and compensated cirrhosis who were treated with GLE/PIB at a single center in Taiwan. Sustained virological response (SVR) and adverse events (AEs) were evaluated. Among the 159 patients, 91 and 68 were treated with GLE/PIB for 8 and 12 weeks, respectively. In the per protocol analysis, both the 8- and 12-week groups achieved 100% SVR (87/87 vs. 64/64); and in the evaluable population analysis, 95.6% (87/91) of the 8-week group and 94.1% (64/68) of the 12-week group achieved SVR. The most commonly reported AEs, which included pruritus (15.4% vs. 26.5%), abdominal discomfort (9.9% vs. 5.9%), and skin rash (5.5% vs. 5.9%), were mild for the 8- and 12-week groups. Two patients in the 8-week group exhibited total bilirubin elevation over three times the upper normal limit. One of these two patients discontinued GLE/PIB treatment after 2 weeks but still achieved SVR. Both 8- and 12-week GLE/PIB treatments are safe and effective for patients of Taiwanese ethnicity with HCV and compensated cirrhosis.https://doi.org/10.1371/journal.pone.0272567 |
| spellingShingle | Yung-Hsin Lu Chung-Kuang Lu Chun-Hsien Chen Yung-Yu Hsieh Shui-Yi Tung Yi-Hsing Chen Chih-Wei Yen Wei-Lin Tung Kao-Chi Chang Wei-Ming Chen Sheng-Nan Lu Chao-Hung Hung Te-Sheng Chang Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting. PLoS ONE |
| title | Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting. |
| title_full | Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting. |
| title_fullStr | Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting. |
| title_full_unstemmed | Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting. |
| title_short | Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting. |
| title_sort | comparison of 8 versus 12 weeks of glecaprevir pibrentasvir for taiwanese patients with hepatitis c and compensated cirrhosis in a real world setting |
| url | https://doi.org/10.1371/journal.pone.0272567 |
| work_keys_str_mv | AT yunghsinlu comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting AT chungkuanglu comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting AT chunhsienchen comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting AT yungyuhsieh comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting AT shuiyitung comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting AT yihsingchen comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting AT chihweiyen comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting AT weilintung comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting AT kaochichang comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting AT weimingchen comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting AT shengnanlu comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting AT chaohunghung comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting AT teshengchang comparisonof8versus12weeksofglecaprevirpibrentasvirfortaiwanesepatientswithhepatitiscandcompensatedcirrhosisinarealworldsetting |